Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409587 · ClinicalTrials.gov registry record · Phase 4
Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump
A Phase 4 study, sponsored by Mountain Diabetes and Endocrine Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT04409587 is a Phase 4 study that has completed, run by Mountain Diabetes and Endocrine Center. The registered enrollment target is 59 participants.
The verdict
NCT04409587, a Phase 4 study, has completed, sponsored by Mountain Diabetes and Endocrine Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this investigator-initiated trial is to compare the effect of a daily injection of insulin degludec vs. basal insulin delivery via Continuous Subcutaneous Insulin Infusion (CSII), both in combination with bolus insulin delivery via the patient's usual insulin pump with insulin aspart, on glycemic variability, overall blood glucose control and incidence of hypoglycemia, all assessed by continuous glucose monitor (CGM), as well as patient satisfaction, in patients with type 1 diabetes currently using CSII.
Interventions
- DRUG Aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2020-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04409587
The ClinicalTrials.gov registry entry for NCT04409587 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mountain Diabetes and Endocrine Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspart is the first listed.
NCT04409587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04409587 about?
NCT04409587 is a clinical study titled "Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump". The purpose of this investigator-initiated trial is to compare the effect of a daily injection of insulin degludec vs. basal insulin delivery via Continuous Subcutaneous Insulin Infusion (CSII), both in combination with bolus insulin delivery via the patient's usual insulin pump with insulin aspart,...
What is the current status of trial NCT04409587?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2018-04-12. Estimated completion is 2020-11-01.
What interventions are being tested in trial NCT04409587?
The interventions under investigation include: Aspart (DRUG).
Who is sponsoring clinical trial NCT04409587?
This trial is sponsored by Mountain Diabetes and Endocrine Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.